Switching from Intravitreal Ranibizumab to Bevacizumab for
Age-Related Macular Degeneration

<table>The mean <svg height="14.2" id="M20" style="vertical-align:-2.73372pt" version="1.1" viewbox="0 0 58.299999 14.2" width="58.299999" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,14.2)">
<g transform="translate(72,-60.64)">
<text transform="matrix(1,0,0,-1,-71.95,63.41)">
<tspan style="font-size: 12.50px; " x="0" y="0">l</tspan>
<tspan style="font-size: 12.50px; " x="3.4758339" y="0">o</tspan>
<tspan style="font-size: 12.50px; " x="9.727334" y="0">g</tspan>
<tspan style="font-size: 12.50px; " x="18.054333" y="0">M</tspan>
<tspan style="font-size: 12.50px; " x="29.169498" y="0">A</tspan>
<tspan style="font-size: 12.50px; " x="38.196667" y="0">R</tspan>
</text>
</g>
</g>
</svg> of the best-corrected visual acuity (BCVA) at each of the visits. There were no statistical significant differences between any of the points and the preswitching value.</table>

International Scholarly Research Notices

fig1

Figure 1

Figure 1: Switching from Intravitreal Ranibizumab to Bevacizumab for
Age-Related Macular Degeneration 

International Scholarly Research Notices

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

Figure 1